Hematopoietic Cell Transplantation for Patients With Hematologic Malignancies Using Related, HLA-Haploidentical Donors
Status:
Recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if engraftment can be achieved safely in patients
with high-risk hematologic malignancies who undergo non-myeloablative transplant with
peripheral stem cells from Human Leukocyte Antigen (HLA) haploidentical donors with pre and
post-transplant cyclophosphamide as immunosuppression.